SITE007-0250

SITE007 (JPN) › SITE007-0250

SITE007-0250

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2026-06-15

enrolled

AEs

4

Serious

1

Dropout signal

–

Adverse events

4

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-05 (study day 66); relationship: RELATED

moderate assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 48); relationship: not assessed

severe assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 46); relationship: not assessed

moderate assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 32); relationship: NOT RELATED; serious criteria: life-threatening

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.